Literature DB >> 26091275

Cyclosporine: a novel therapeutic approach for Burning Mouth Syndrome.

Rosita Saraceno1, Bruno Lorè, Athanasios Pavlidis, Maria Karaiskou, Claudio Arcuri, Sergio Chimenti, Roberto Magnato.   

Abstract

BACKGROUND: The aim of this paper was to evaluate the efficacy and safety of topical cyclosporine applied as mouthwash in the treatment of burning mouth syndrome (BMS).
METHODS: This was a prospective and pilot study conducted by the Department of Dermatology of the University of Rome Tor Vergata. Patients were treated with cyclosporine topically applied as mouthwash for 4 weeks. Clinical improvement was assessed using a 5 grade clinical evaluation scale and a visual analogue scale from 0 to 10 was also used to evaluate the burning symptoms.
RESULTS: Fifteen patients between 22-85 years (61.1±19.3), 11 female and 4 male, with a mean duration of BMS of 12.5 months, completed the study. Five out of 15 patients presented a marked improvement, 6 patients showed a moderate response, 3 patients had a slight improvement and 1 patient did not show any change. The VAS showed a reduction from 8.7 to 3.5. Adverse events were not reported.
CONCLUSIONS: Cyclosporine mouthwash appeared to be safe and beneficial for reducing the burning sensation in patients with BMS representing an alternative therapy in this condition.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26091275

Source DB:  PubMed          Journal:  G Ital Dermatol Venereol        ISSN: 0392-0488            Impact factor:   2.011


  1 in total

1.  Management of burning mouth syndrome.

Authors:  Vagish Kumar Laxman Shanbhag
Journal:  J Pharm Bioallied Sci       Date:  2016 Apr-Jun
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.